Overview:

Global Top 10 Pharmaceutical Companies report profiles the leading players in the pharmaceutical market worldwide. The sector consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

The report analyzes the sector in terms of market value, market share, market segmentation, key drivers and resistors, trends and competitive positioning. It includes details of the top 10 companies in the industry along with five-year financial analysis and in-depth SWOT profiles.

Key features of this report

Market dynamics in the global pharmaceutical sector during the period 2009–14
The market's key drivers and resistors
Trends in the pharmaceutical sector
Identification and analysis of the top 10 pharmaceutical players globally
Details of the performance of the top 10 companies during 2005–09

Scope of this report

Analyze the global top 10 pharmaceutical and the sector overall using key industry metrics, including market value, market shares, market segmentation and growth forecasts
Assess the intensity of the competition in the industry using the five forces model, covering the degree of rivalry, the danger posed by substitutes, the risk represented by new entrants, buyer power and supplier power
Investigate the strengths, weaknesses, opportunities and threats and access five-year financial analysis for the top 10 players in the sector
Peruse descriptive profiles of the leading players, including details of the strategic initiatives undertaken in the last 12 months
Understand the major issues affecting the global pharmaceutical sector
Predict the key growth areas in the industry arising from changes in customers’ preferences and the economic environment
Save time, money and resources by analyzing the top 10 pharmaceutical companies using this report

Key issues examined

An examination of the performance of the global pharmaceutical sector on the basis of sales and volume and their respective growth patterns over the past five years
In-depth analysis of strengths, weaknesses, opportunities and threats for the top 10 pharmaceutical companies along with business overviews and financial summaries
Benchmarking of the financial performance of each of the top 10 pharmaceutical players for the past five years, including comparisons of revenues, profitability analysis and industry-specific ratios

Highlights:

The global pharmaceuticals market generated total revenues of $644.2 billion in 2009, representing a compound annual growth rate (CAGR) of 4.3% for the period spanning 2005–09.

The top 10 global pharmaceutical companies recorded revenues of $361.3 billion during 2009, an increase of 3.7% over 2008. The operating profit of these companies was $84.5 billion during 2009, an increase of 3.6% over 2008. The net profit was $81.3 billion in 2009, an increase of 25% over 2008.

The average operating profit margin of the top 10 companies slightly declined to 23.2% in 2009 from the previous year’s margin of 23.3%. In contrast, the average net profit margin grew to record 26.3% in 2009 as compared with 20.2% in 2008.

Since 2005, the global pharmaceuticals market has witnessed moderate growth across different geographies. The market growth is expected to decelerate through to 2014 due to increased number of patent expiries and intensifying competition from generics.

Key questions answered in this report

What was the market size of the global pharmaceutical sector by value in 2009?
What will the market size be during 2009–14?
What are the trends in the global pharmaceutical sector?
Who are the top 10 players in the industry?
What are the strengths of the top 10 companies in the global pharmaceutical sector?
What are the weaknesses of the top 10 players?
What are the growth opportunities for the top 10 firms?
What are the threats faced by global pharmaceutical companies

Executive Summary 7
Industry analysis 7
Industry definition 7
Research highlights 7
Top 10 companies landscape 8
Market Value 9
Market Forecast 10
Market Segmentation: Product 11
Market Segmentation: Geographic 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Substitutes 17
Rivalry 18
Top 10 Companies Landscape 19
Overview 19
Revenue analysis 23
Financial performance analysis 25
Company Reports 30
Pfizer 30
F. Hoffmann-La Roche 36
Novartis 42
GlaxoSmithKline 49
Sanofi-Aventis 56
AstraZeneca 64
Abbott Laboratories 74
Merck & Co. 80
Eli Lilly and Company 86
Bristol-Myers Squibb Company 94
Five-Year Financial Information 99
Pfizer 99
F. Hoffman-La Roche 102
Novartis 105
GlaxoSmithKline 108
Sanofi-Aventis 111
AstraZeneca 114
Abbott Laboratories 117
Merck & Co. 120
Eli Lilly and Company 123
Bristol-Myers Squibb Company 126
Appendix 129


FIGURES
Figure 1: Global pharmaceuticals market ($ billion), 2005–09 9
Figure 2: Global pharmaceuticals market forecast ($ billion), 2009–14 10
Figure 3: Global pharmaceuticals market segmentation: product (% share), 2009 11
Figure 4: Global pharmaceuticals market segmentation: geography (% share), 2009 12
Figure 5: Forces driving competition in the global pharmaceuticals market, 2009 13
Figure 6: Drivers of buyer power in the global pharmaceuticals market, 2009 14
Figure 7: Drivers of supplier power in the global pharmaceuticals market, 2009 15
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2009 16
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2009 17
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market, 2009 18
Figure 11: Revenues of global top 10 pharmaceutical companies ($m), FY2009 20
Figure 12: Revenue growth of the global top 10 pharmaceutical companies, FY2007–09 24
Figure 13: Operating performance analysis, FY2009 26
Figure 14: Net profit analysis, FY2009 27

TABLES
Table 1: Global pharmaceutical market ($ billion), 2005–09 9
Table 2: Global pharmaceuticals market forecast ($ billion), 2009–14 10
Table 3: Global pharmaceuticals market segmentation: product (% share), 2009 11
Table 4: Global pharmaceuticals market segmentation: geography (% share), 2009 12
Table 5: Revenues and sales of global top 10 pharmaceutical companies ($m), FY2009 20
Table 6: Revenue growth of global top 10 pharmaceutical companies, FY2007–09 23
Table 7: Key financials of the global top 10 pharmaceutical companies, FY2009 25
Table 8: Key industry-specific ratios, FY2009 28
Table 9: Pfizer: financial and operational highlights, 2005–09 ($m) 99
Table 10: Pfizer: key industry-specific ratios, 2005–09 101
Table 11: F. Hoffman-La Roche: financial and operational highlights, 2005–09 ($m) 102
Table 12: F. Hoffman-La Roche: key industry-specific ratios, 2005–09 104
Table 13: Novartis: financial and operational highlights, 2005–09 ($m) 105
Table 14: Novartis: key industry-specific ratios, 2005–09 107
Table 15: GlaxoSmithKline: financial and operational highlights, 2005–09 ($m) 108
Table 16: GlaxoSmithKline: key industry-specific ratios, 2005–09 110
Table 17: Sanofi-Aventis: financial and operational highlights, 2005–09 ($m) 111
Table 18: Sanofi-Aventis: key industry-specific ratios, 2005–09 113
Table 19: AstraZeneca: financial and operational highlights, 2005–09 ($m) 114
Table 20: AstraZeneca: key industry-specific ratios, 2005–09 116
Table 21: Abbott Laboratories: financial and operational highlights, 2005–09 ($m) 117
Table 22: Abbott Laboratories: key industry-specific ratios, 2005–09 119
Table 23: Merck & Co.: financial and operational highlights, 2005–09 ($m) 120
Table 24: Merck & Co.: key industry-specific ratios, 2005–09 122
Table 25: Eli Lilly and Company: financial and operational highlights, 2005–09 ($m) 123
Table 26: Eli Lilly and Company: key industry-specific ratios, 2005–09 125
Table 27: Bristol-Myers Squibb Company: financial and operational highlights, 2005–09 ($m) 126
Table 28: Bristol-Myers Squibb Company: key industry-specific ratios, 2005–09 128